The first immunoassay, an assay for human insulin, was described by Rosalyn Yalow and Solomon Berson back in 1959. This innovation has been a fundamental contribution to diagnostics in the areas of medicine, veterinary, agricultural, pharmaceutical and life sciences.
The last 50 years has spawned a wide number of immunoassay techniques, one of these, lateral flow immunochromatography has enabled testing to move from the laboratory to the point of contact. Providing results in minutes, these lateral flow rapid tests are straightforward to use and have found wide application.
Lateral flow immunoassays can detect both small and large molecules and can be applied to any protein, hapten, nucleic acid or amplicon. Use of a visual label, such as gold, carbon, or coloured latex nanoparticles, allows for a rapid qualitative test which can be further enhanced using a reader to convert to a fully quantitative readout.
At the heart of the immunoassay is a binding reagent. For this article, we’ll use the term antibody to cover any protein, affirmer, anti-ligand or DNA-based aptamer that might be deployed. The antibody can be tuned to bind the target analyte with exceptional specificity, enabling minute concentrations to be detected in the presence of structurally related molecules.
The flexibility of the immunoassay format has led to a plethora of techniques which is impossible to cover in this article. Here we consider the two main approaches that have had wide commercial success in lateral flow devices:
Each format has pros and cons depending on the analyte, the antibody, sample matrix and concentration range of interest. Generally, non-competitive immunoassay has a lower limit of detection (analytical sensitivity) compared to the competitive format. This is typically picogram/mL (parts per trillion) for non-competitive compared to nanogram/mL (parts per billion) for the competitive format. In situations where a significantly high analyte concentrations might be encountered, non-competitive formats can suffer from the high-dose hook effect which can yield to false results. The competitive format cannot have a high-dose hook effect. With many Man years experience and over 200 contract Research and Development (R&D) projects completed, we are perfectly placed to advise and guide you on the most suitable approach for your test.
Either LFD format can be manufactured very reproducibly using state-of-the-art production equipment and facilities. Abingdon Health has ISO 13485:2003 (including EN ISO 13485:2012) & ISO 9001:2008 accreditation for the development and manufacture of lateral flow immunoassay diagnostics. In addition to this Abingdon Health’s manufacturing facilities are GMP compliant, with the U.S. Food and Drug Administration (FDA), for the design, development and manufacture of lateral flow devices, and device readers for in vitro diagnostic medical use.
© Abingdon Health 2017